Cediranibisanindoleetherquinazolinederivativewithantineoplasticactivities.Competingwithadenosinetriphosphate,cediranibbindstoandinhibitsallthreevascularendothelialgrowthfactorreceptor(VEGF-1,-2,-3)tyrosinekinases,therebyblockingVEGF-signaling,angiogenesis,andtumorcellgrowth.

MedKooCat#:200690
Name:Cediranib
CAS#:288383-20-0(freebase)
ChemicalFormula:C25H27FN4O3
ExactMass:450.20672
MolecularWeight:450.5
ElementalAnalysis:C,66.65;H,6.04;F,4.22;N,12.44;O,10.65.


Synonym:AZD2171;AZD2171;AZD-2171;Cediranib;USbrandname:Recentin.Foreignbrandname:Recentin.

IUPAC/ChemicalName:4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline

InChiKey:XXJWYDDUDKYVKI-UHFFFAOYSA-N

InChiCode:InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3

SMILESCode:COC1=CC2=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)N=CN=C2C=C1OCCCN5CCCC5


TechnicalData

Appearance:
whitesolidpowder

Purity:
>98%(orrefertotheCertificateofAnalysis)

ShippingCondition:
Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:
Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:
SolubleinDMSO,notinwater

ShelfLife:
>2yearsifstoredproperly

DrugFormulation:
ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:
0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:
293490


AdditionalInformation

Accordingtohttp://en.wikipedia.org/wiki/Cediranib,Cediranibisapotentinhibitorofvascularendothelialgrowthfactor(VEGF)receptortyrosinekinases.ItisbeingdevelopedbyAstraZenecaasapossibleanti-cancerchemotherapeuticagentfororaladministration.Beginningin2007,itisundergoingPhaseIclinicaltrialsforthetreatmentofnon-smallcelllungcancer,kidneycancer,andcolorectalcancerinadults,aswellastumorsofthecentralnervoussysteminchildren.PhaseItrialsofinteractionswithotherdrugsusedincancertreatmentarealsounderway.OnFebruary27,2008,AstraZenecaannouncedthattheuseofRecentininnon-smallcelllungcancerwillnotprogressintophaseIIIafterfailingtomeetitsmaingoal.On8thMarch2010,AstraZenecaissuedapress-releasestatingthatRecentinhadfailedPhaseIIIclinicaltrialsforuseinfirst-linemetastaticcolorectalcancerwhenitwascomparedclinicallywiththemarket-leaderAvastin.
 
 


References

1:MorelliMP,BrownAM,PittsTM,TentlerJJ,CiardielloF,RyanA,JürgensmeierJM,EckhardtSG.Targetingvascularendothelialgrowthfactorreceptor-1and-3withcediranib(AZD2171):effectsonmigrationandinvasionofgastrointestinalcancercelllines.MolCancerTher.2009Sep;8(9):2546-58.Epub2009Sep15.PubMedPMID:19755510;PubMedCentralPMCID:PMC2819052.

2:TaoLY,LiangYJ,WangF,ChenLM,YanYY,DaiCL,FuLW.Cediranib(recentin,AZD2171)reversesABCB1-andABCC1-mediatedmultidrugresistancebyinhibitionoftheirtransportfunction.CancerChemotherPharmacol.2009Oct;64(5):961-9.Epub2009Mar3.PubMedPMID:19255759.

3:SiemannDW,BrazelleWD,JürgensmeierJM.Thevascularendothelialgrowthfactorreceptor-2tyrosinekinaseinhibitorcediranib(Recentin;AZD2171)inhibitsendothelialcellfunctionandgrowthofhumanrenaltumorxenografts.IntJRadiatOncolBiolPhys.2009Mar1;73(3):897-903.PubMedPMID:19215823;PubMedCentralPMCID:PMC2788500.

4:RobertsonJD,BotwoodNA,RothenbergML,SchmollHJ.PhaseIIItrialofFOLFOXplusbevacizumaborcediranib(AZD2171)asfirst-linetreatmentofpatientswithmetastaticcolorectalcancer:HORIZONIII.ClinColorectalCancer.2009Jan;8(1):59-60.PubMedPMID:19203899.

5:WilliamsKJ,TelferBA,ShannonAM,BaburM,StratfordIJ,WedgeSR.Inhibitionofvascularendothelialgrowthfactorsignallingusingcediranib(RECENTIN;AZD2171)enhancesradiationresponseandcausessubstantialphysiologicalchangesinlungtumourxenografts.BrJRadiol.2008Oct;81SpecNo1:S21-7.PubMedPMID:18819995.

6:BradleyDP,TessierJJ,LaceyT,ScottM,JürgensmeierJM,OdedraR,MillsJ,KilburnL,WedgeSR.Examiningtheacuteeffectsofcediranib(RECENTIN,AZD2171)treatmentintumormodels:adynamiccontrast-enhancedMRIstudyusinggadopentate.MagnResonImaging.2009Apr;27(3):377-84.Epub2008Sep23.PubMedPMID:18814988.

7:CurwenJO,MusgroveHL,KendrewJ,RichmondGH,OgilvieDJ,WedgeSR.Inhibitionofvascularendothelialgrowthfactor-asignalinginduceshypertension:examiningtheeffectofcediranib(recentin;AZD2171)treatmentonbloodpressureinratandtheuseofconcomitantantihypertensivetherapy.ClinCancerRes.2008May15;14(10):3124-31.PubMedPMID:18483380.

8:LaurieSA,GauthierI,ArnoldA,ShepherdFA,EllisPM,ChenE,GossG,PowersJ,WalshW,TuD,RobertsonJ,PuchalskiTA,SeymourL.PhaseIandpharmacokineticstudyofdailyoralAZD2171,aninhibitorofvascularendothelialgrowthfactortyrosinekinases,incombinationwithcarboplatinandpaclitaxelinpatientswithadvancednon-small-celllungcancer:theNationalCancerInstituteofCanadaclinicaltrialsgroup.JClinOncol.2008Apr10;26(11):1871-8.PubMedPMID:18398152.

9:SmithNR,JamesNH,OakleyI,WainwrightA,CopleyC,KendrewJ,WomersleyLM,JürgensmeierJM,WedgeSR,BarryST.AcutepharmacodynamicandantivasculareffectsofthevascularendothelialgrowthfactorsignalinginhibitorAZD2171inCalu-6humanlungtumorxenografts.MolCancerTher.2007Aug;6(8):2198-208.PubMedPMID:17699717.

10:HanrahanEO,HeymachJV.Vascularendothelialgrowthfactorreceptortyrosinekinaseinhibitorsvandetanib(ZD6474)andAZD2171inlungcancer.ClinCancerRes.2007Aug1;13(15Pt2):s4617-22.Review.PubMedPMID:17671152.